Role of sex and sex hormones in PD-L1 expression in NSCLC: clinical and therapeutic implications
V Rodriguez-Lara, G Soca-Chafre… - Frontiers in …, 2023 - frontiersin.org
Currently, immunotherapy based on PD-1/PD-L1 pathway blockade has improved survival
of non-small cell lung cancer (NSCLC) patients. However, differential responses have been …
of non-small cell lung cancer (NSCLC) patients. However, differential responses have been …
γδ T cells and the PD-1/PD-L1 axis: a love–hate relationship in the tumor microenvironment
J Liu, M Wu, Y Yang, Z Wang, S He, X Tian… - Journal of Translational …, 2024 - Springer
Gamma delta (γδ) T cells demonstrate strong cytotoxicity against diverse cancer cell types in
an MHC-independent manner, rendering them promising contenders for cancer therapy …
an MHC-independent manner, rendering them promising contenders for cancer therapy …
[HTML][HTML] Increasing membrane polyunsaturated fatty acids sensitizes non-small cell lung cancer to anti-PD-1/PD-L1 immunotherapy
S La Vecchia, S Fontana, IC Salaroglio, DP Anobile… - Cancer Letters, 2024 - Elsevier
Immune checkpoints inhibitors (ICIs) as anti-PD-1/anti-PD-L1 have been approved as first-
line treatment in patients with non-small cell lung cancer (NSCLC), but only 25% of patients …
line treatment in patients with non-small cell lung cancer (NSCLC), but only 25% of patients …
Estrogen receptor and immune checkpoint inhibitors: new partners in lung cancer?
K Valencia, LM Montuenga, A Calvo - Clinical Cancer Research, 2023 - AACR
The influence of sex on immunotherapy response in patients with non–small cell lung
cancer (NSCLC) had been studied with no clear conclusions. An article in this issue reports …
cancer (NSCLC) had been studied with no clear conclusions. An article in this issue reports …
[HTML][HTML] Role of the TME in immune checkpoint blockade resistance of non-small cell lung cancer
Y Dai, X Tian, X Ye, Y Gong, L Xu… - Cancer Drug Resistance, 2024 - oaepublish.com
Primary and secondary resistance to immune checkpoint blockade (ICB) reduces its efficacy.
The mechanisms underlying immunotherapy resistance are highly complex. In non-small …
The mechanisms underlying immunotherapy resistance are highly complex. In non-small …
[HTML][HTML] The causal nexus between diverse smoking statuses, potential therapeutic targets, and NSCLC: insights from Mendelian randomization and mediation …
Z Cao, S Zhao, T Wu, H Ding, Z Tian, F Sun… - Frontiers in …, 2024 - pmc.ncbi.nlm.nih.gov
Objective Lung cancer, the most prevalent malignancy, is typically diagnosed at an
advanced stage. Smoking is a pivotal risk factor for NSCLC, yet the impact of various …
advanced stage. Smoking is a pivotal risk factor for NSCLC, yet the impact of various …
Sexual Dimorphism in Immunity and Metabolism: Unraveling the Impact on Response to Cancer Immunotherapy
AC Soloff, HM Udoh, CE Bardawil… - Journal of Cancer …, 2024 - scientificarchives.com
A recent observational study by Jin et al., found male sex and pretreatment weight loss to be
associated with worse progression free survival (PFS) and overall survival (OS) in non-small …
associated with worse progression free survival (PFS) and overall survival (OS) in non-small …